Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SIPL protein pseudogene (ENSG00000233877) is classified as a non-coding pseudogene, meaning it is a DNA sequence highly similar to a protein-coding gene but rendered non-functional by mutations or deletions preventing proper transcription or translation[1][2][4]. While pseudogenes in general were once considered "junk DNA," research indicates that some can be transcribed into non-coding RNAs and may regulate the expression of their parent or other genes at the RNA level[2][3][4]. However, there is no direct evidence that the SIPL protein pseudogene plays a functional or regulatory role, nor does it encode a therapeutic target or a protein. There are no known drug interactions, established mechanism of action, or clinical disease associations specific to this pseudogene. It is not used as a biomarker and has no notable safety concerns. Its main relevance is as part of genome annotation and studies on genome evolution and gene regulation[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SIPL protein pseudogene.